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1. Introduction 
Tissue ischemia reperfusion (IR) remains of the main causes of permanent or transient damage with serious 
implications on adjacent organs and certainly on patients’ health. Although important progress has been made regarding the 
usage of erythropoietin (Epo) in managing this kind of damages, satisfactory answers have not been given yet to 
fundamental questions, as, by what velocity this factor acts, when it should be administered, and in which dosage. The 
particularly satisfactory action of Epo in stem blood cells recovery has been noted in several performed experiments. 
However, just few relative reports were found concerning Epo trial in IR experiments, not covering completely this 
particular matter. A meta-analysis of 14 published seric variables, coming from the same experimental setting, tried to 
provide a numeric evaluation of the Epo efficacy at the same endpoints (Table 1). Furthermore, several publications 
addressed trials of other similar molecules of growth factors to which the studied molecule also belongs to. 
The aim of this experimental study was to examine the effect of Epo on rat model and particularly in a liver IR 
protocol. The effect of that molecule was studied by measuring the blood mean γ-glutamyltransferase (γGT) levels.  
 
 
 
Abstract 
The aim of this experimental study was to examine the effect of 
erythropoietin on rat model and particularly in an ischemia reperfusion (IR) 
protocol. The effect of that molecule was studied biochemically using blood 
mean γ-glutamyl transferase (γGT) levels.   
40 rats of mean weight 247.7 g were used in the study.  γGT levels 
were measured at 60 min (groups A and C) and at 120 min (groups B and D) of 
reperfusion. Erythropoietin was administered only in groups C and D. 
Results were that Epo administration non-significantly decreased the 
γGT levels by 12.70%±13.11% results of paired t-test (p= 0.3541). Reperfusion 
time kept non-significantly increased the γGT levels by 6.35%±13.24% 
(P=0.6264). However, erythropoietin administration and reperfusion time 
together produced a non-significant combined effect in keeping decreased the 
γGT levels by 4.62%±7.97% (P= 0.5534). 
Conclusions are that erythropoietin administration whether it 
interactedor not with reperfusion time have non significant short – term 
decreasing effects on γGT levels.  
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2. Materials and methods 
2.1 Experimental animals 
This experimental study was lisenced by Veterinary Address of East Attiki Prefecture under 3693/12-11-2010 & 
14/10-1-2012 decisions. All settings needed for the study including consumables, equipment and substances used, were a 
courtesy of Exprerimental Research Center of ELPEN Pharmaceuticals Co. Inc. S.A. at Pikermi, Attiki. Accepted standards 
of humane animal care were adopted for Albino female Wistar rats. Normal housing in laboratory 7 days before the 
experiment included continuous access to water and food. The experiment was acute, that means that awakening and 
preservation of the rodents was not following the experiment. They were randomly delivered to four experimental groups 
by 10 animals in each one. Ischemia for 45 min followed by reperfusion for 60 min (Group A). Ischemia for 45 min 
followed by reperfusion for 120 min (Group B). Ischemia for 45 min followed by immediate Epo intravenous (IV) 
administration and reperfusion for 60 min (Group C). Ischemia for 45 min followed by immediate Epo IV administration 
and reperfusion for 120 min (Group D). The molecule Epo dosage was 10 mg/Kg body weight of animals. 
At first, the animals were submitted into prenarcosis followed by general anesthesia. The detailed anesthesiologic 
technique is described in related references [1]. Oxygen supply, electrocardiogram and acidometry were continuously 
provided during whole experiment performance.   
The protocol of IR was followed. Ischemia was caused by forceps clamping inferior aorta over renal arteries for 45 
min after laparotomic access had been achieved. Reperfusion was induced by removing the clamp and reestablishment of 
inferior aorta patency. The molecules were administered at the time of reperfusion, through inferior vena cava after 
catheterization had been achieved. The γGT levels measurements were performed at 60 min of reperfusion (for groups A 
and C) and at 120 min of reperfusion (for groups B and D). The mean weight of the forty (40) female Wistar albino rats 
used was 231.875 g [Std. Dev: 36.59703 g], with min weight ≥ 165 g and max weight ≤ 320 g. Rats' weight could be 
potentially a confusing factor, e.g. the more obese rats to have greater γGT levels. This suspicion was investigated. 
 
2.2 Model of ischemia-reperfusion injury 
Control groups: 20 control rats (mean mass 252.5 g [Std. Dev: 39.31988 g] suffered by ischemia for 45 min followed by 
reperfusion.  
Group A: Reperfusion lasted for 60 min (n=10 controls rats) mean mass 243 g [Std. Dev: 45.77724 g], mean γGT levels 
1.7 IU/L [Std. Dev: 0.6749486 IU/L] (Table 2).
   
Group B: Reperfusion lasted for 120 min (n=10 controls rats) mean mass 262 g [Std. Dev: 31.10913 g], mean γGT levels 
1.7 IU/L [Std. Dev: 0.6749486 IU/L] (Table 2).
   
Erythropoietin group: 20 Epo rats (mean mass 242.9 g [Std. Dev: 30.3105 g] suffered by ischemia for 45 min followed by 
reperfusion in the beginning of which 10 mg Epo /kg body weight were IV administered.  
Group C: Reperfusion lasted for 60 min (n=10 Epo rats) mean mass 242.8 g [Std. Dev: 29.33636 g], mean γGT levels 1.4 
IU/L [Std. Dev: 0.5163978 IU/L] (Table 2).
   
Group D: Reperfusion lasted for 120 min (n=10 Epo rats) mean mass 243 g [Std. Dev: 32.84644 g], mean γGT levels 1.6 
IU/L [Std. Dev: 0.6992059 IU/L] (Table 2). 
 
3. Results  
Weight comparison of everyone from 4 rats groups initially was performed with each other from 3 remained 
groups applying statistical paired t-test (Table 3). Any emerging significant difference among γGT levels, was investigated 
whether owed in the above mentioned significant weight correlations. γGT levels comparison of everyone from 4 rats 
groups initially was performed with each other from 3 remained groups applying statistical paired t-test (Table 3). Applying 
generalized linear models (GLM) with dependant variable the γGT levels and independent variables the Epo administration 
or no, the reperfusion time and their interaction, resulted in: Epo administration non-significantly decreased the γGT levels 
by 0.2 IU/L [-0.6048788 IU - 0.2048788 IU/L] (P= 0.3236). This finding was in accordance with the results of paired t-test 
(p=0.3847). Reperfusion time kept non-significantly increased the γGT levels by 0.1 IU/L [-0.3088548 IU - 0.5088548 
IU/L] (P= 0.6234), in accordance also with paired t-test (P=0.6295). However, erythropoietin administration and 
reperfusion time together produced a non-significant combined effect in keeping decreased the γGT levels by 0.0727273 
IU/L [-0.3189142 IU - 0.1734597 IU/L] (P= 0.5534). Reviewing the above and table 3, the tables 4 and 5 sum up 
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concerning the alteration influence of Epo in connection with reperfusion time. Inserting the rats weight as independent 
variable at GLM, a non-significant relation turns on γGT levels (p= 0.7483), so as to further investigation is not needed. 
 
Table 1: The erythropoietin (Epo) influence (+SD) on the levels of some seric
1
 variables concerning reperfusion (rep) 
time 
Variable 1h rep 
p-
value 
1.5h rep 
p-
value 
2h rep 
p-
value 
interaction of 
Epo and rep 
p-
value 
white blood 
cells          
+24.01%+13.38%   0.1012     +22.09%+9.11%      0.0351 +20.17%+12.94%     
0.0902   
+14.63%+5.40%   0.0080 
hematocrit     +0.14%+2.89%       0.9626         -0.61%+2.37%       0.8072         -1.37%+4.05% 0.7485        +0.24%+1.38%        0.8586 
mean 
corpuscular 
hemoglobin 
+0.01%+1.29%   0.9904     +0.67%+0.80%   0.3549     +1.34%+1.08%   0.1509    -0.36%+0.47%    0.4430 
platelet 
distribution 
width 
+1.60%+0.80%   0.0765      +1.36%+0.58%      0.0205 +1.13%+0.74%         
0.1152    
+0.37%+0.37%   0.0615 
plateletcrit -16.47%+10.40%    0.0921     -13.74%+7.01%       0.0158 -11.01%+7.34% 0.0882    -6.88%+3.69%    0.0615 
uric acid                        +10.13%+15.10%    0.4917    +15.86%+10.21%    0.1408 +21.59%+15.45% 0.1940    +9.33%+6.16%   0.1264 
total protein                -0.02%+2.47%      0.9904     -1.27%+1.51%         0.3721       -2.52%+2.03% 0.1509      -0.68%+2.48%       0.4430 
alkaline 
phosphatase   
+0.20%+18.57%     0.9904    +10.70%+12.78%    0.3549    +21.20%+17.11%    0.1509     +5.79%+7.72%     0.4430 
acid 
phosphatase          
+0.06%+5.79%     0.9904    +3.11%+3.71%         0.3172     +6.16%+4.97%     0.1509     +1.68%+2.23%       0.4430 
CPK  +0.15%+14.09%     0.9904    +7.91%+9.44%         0.3549    +15.67%+12.65%    0.1509     +4.28%+5.70%      0.4430 
LDH                          
+0.08%+7.92%      
0.9904     +4.48%+5.35%         0.3549      +8.89%+7.17%    0.1509     +2.42%+3.22%      0.4430 
sodium +0.72%+0.74%       0.3054    +0.21%+0.63%        0.7136    -0.29%+1.09% 0.7670     -0.11%+0.38%     0.7531 
phosphorus +1.92%+5.25% 0.6982 +3.95%+3.35% 0.2100 +5.98%+4.81% 0.2930 +2.45%+2.01% 0.2168 
progesterone -0.20%+18.65%     0.9904    -8.86%+10.58%        0.3549    -17.53%+14.15%         0.1509     -4.79%+6.39%     0.4430 
mean   +1.59%+8.41% 0.6900   +3.27%+9.12% 0.3147 +4.95%+11.82% 0.2394 +2.02%+5.41% 0.3704 
 
Table 2: Weight and γGT levels and Std. Dev. of groups 
Groups Variable Mean Std. Dev 
A Weight 243 gr                                       45.77724 gr 
γGT 1.7  IU/L 0.6749486 IU/L 
B Weight 262 gr 31.10913 gr 
γGT 1.7  IU/L 0.6749486 IU/L 
C Weight 242.8 gr 29.33636 gr 
γGT 1.4 IU/L 0.5163978 IU/L 
D Weight 243 gr 32.84644 gr 
γGT 1.6 IU/L 0.6992059 IU/L 
 
Table 3: Statistical significance of mean values difference for groups (DG) after statistical paired t test application 
DG Variable   Difference p-value    
Α-Β                    Weight -19 gr 0.2423 
γGT 0 IU/L 1.0000 
A-C Weight 0,2 gr 0.9900 
γGT 0.3 IU/L 0.1934 
A-D Weight 0 gr 1.0000 
γGT 0.1 IU/L 0.6783 
B-C Weight 19,2 gr 0.2598 
γGT 0.3 IU/L 0.2789 
B-D Weight 19 gr 0.1011 
γGT 0.1 IU/L 0.8114 
C-D Weight -0,2 gr 0.9883 
γGT -0.2 IU/L 0.4433 
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Table 4: The decreasing influence of erythropoietin in connection with reperfusion time 
Decrease 95% c. in. Reperfusion time 
p-values 
t-test glm 
0.3 IU/L 
 
-0.8646058 IU - 0.2646058 IU/L     1h 0.1934 0.2790 
0.2 IU/L       -0.6048788 IU - 0.2048788 IU/L 1.5h    0.3847              0.3236   
0.1 IU/L -0.7456515 IU - 0.5456515 IU/L 2h 0.8114                0.7486     
-0.1 IU/L       -0.3088548 IU - 0.5088548 IU/L          reperfusion time 0.6295               0.6234 
0.0727273 IU/L  -0.3189142 IU - 0.1734597 IU/L   interaction  0.5534 
 
Table 5: The decreasing influence of erythropoietin in connection with reperfusion time 
Decrease ±SD Reperfusion time p-values   
-19.35% ±18.58% 1h 0.2362 
-12.70% ±13.11% 1.5h 0.3541 
-6.06% ±19.96% 2h 0.7800 
+6.35% ±13.24% reperfusion time 0.6264 
-4.62% ±7.97% interaction 0.5534 
 
4. Discussion 
γGT is being considered a reliable index, not only for liver function but also for general metabolism. Its production 
is being influenced by ischemia and particulary by certain mode, as the next references show. Seifert et al[2] did not notice 
significant γGT levels changes over the 14-day assessment period occurring in subjects which ingested 20 g/day of ribose. 
Cutrín et al[3] obtained γGT samples from both ischemic and not kidneys after a standard brief period of unilateral kidney 
IR in rats. γGT activity was found to be increased in both cortical and medullar zones of the ischemic kidneys obtaining a 
net pro-oxidant effect of up-regulated γGT during short-term ischemia. Bounous et al[4] estimated the total activities of 
γGT in the isolated brush border of the entire small bowel reduced by 21% than control values (p < 0.001) after IR of the 
superior mesenteric artery. Enzymatic activity expressed as U/mg protein, is significantly reduced in the case of γGT level 
by 48% than control values. 
Also, γGT level is a factor influenced by Epo. Is suitable Epo dose administration able to restore the rised γGT 
levels? Endre et al[5] found no difference in the incidence of Epo in the primary outcome between placebo and Epo treated 
groups, after randomization triggered by the enzyme γGT concentration product to levels above 46.3 in ICU patients. 
Although the marker elevations were transient, selected patients were determined by more severe illness and at greater risk 
of acute kidney injury, dialysis, or death. Lau et al[6] treated Sprague-Dawley rats by PHE/HQ (1.1 mmol/kg/0.9 mmol/kg, 
ip) and benzene. 2,6-GS-HQ and 2,3,5-GS-HQ were also found in the bone marrow of them. Hydroquinone (HQ) readily 
oxidizes to 1,4-benzoquinone (1,4-BQ) followed by the reductive addition of glutathione (GSH). Hydroquinone (HQ) may 
activate oxygen via redox cycles in biological systems and may also deplete glutathione (GSH). Both these reactions are 
potentially harmful, and they may be involved in hydroquinone-induced development of γGT -positive enzyme-altered foci 
in rat liver. Moreover, 2,6-GS-HQ and 2,3,5-GS-HQ were hematotoxic when administered to rats. All of the HQ-GSH 
conjugates retain the ability to redox cycle and generate reactive oxygen species (ROS), and to arylate target proteins. The 
generation of ROS and alkylation of proteins may both contribute to benzene-mediated myelotoxicity, and the two 
processes may be inter-dependent. Within 18h of administration of PHE/HQ to rats a significant decrease in blood 
lymphocyte count was observed, but erythrocyte counts and hemoglobin concentrations remained within the normal range. 
Stenius et al[7] confirmed also that hydroquinone (HQ) may activate oxygen via redox cycles in biological systems, may 
also deplete glutathione (GSH) and both these reactions are potentially harmful. They studied their possible involvement in 
hydroquinone-induced development of γGT-positive enzyme-altered foci in rat liver. Gold et al[8] faced a young horse with 
erythrocytosis and increased serum γGT levels. Biopsy revealed hepatoblastoma and also bone marrow erythroid 
hyperplasia. Serum Epo concentration was 2.37-fold above upper reference value supporting production by the tumor and 
secondary inappropriate erythrocytosis. This report documents secondary erythrocytosis in a horse with hepatoblastoma. 
Chakraborty et al[9] saw fourfold activity of γGT, a neoplastic marker, in the host cells bearing in Dalton's lymphoma host 
mice. They confirmed the lymphoma progression via modulating erythropoiesis. De Paoli Vitali et al[10] determined
 
serum 
Epo activity non significantly reduced in skiers than normal population (P < 0.01). In athletes Epo, urinary γGT levels, were 
determined before and after a ski race. A significant increase of these variables was found after the competition (P < 0.001). 
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It is concluded that they were not accompanied by a renal hypoxia sufficient to stimulate Epo overproduction during the 
strenuous race. Barroso et al[11] did not predict greater HIV participants-related fatigue by physiological changes 
measurements including γGT, HIV viral load and serum Epo levels, over a 1-year period. 
Nevertheless, Takigawa et al[12] investigated the main factors correlated with the serum γGT activity in healthy 
Japanese people. The mean serum γGT activity was 29 IU/L. γGT activities of males and persons older than 45 years were 
significantly higher than each counterpart. γGT levels were increased significantly with the number of cigarettes smoked per 
day and the frequency of alcohol consumption except for the persons who did not take alcohol. Additionally, γGT was 
significantly correlated with urinary 8-hydroxydeoxyguanine, and with more blood factors including serum tocopherols, 
carotenoids, antioxidative enzymes, lipid peroxide, and free fatty acids than urinary 8-hydroxydeoxyguanine did. γGT had 
significant associations with retinol, 8-hydroxydeoxyguanine, docosahexaenoic acid, and cigarette smoking. They suppose 
the hypothesis that γGT can be used as a marker related with oxidative stress. Onur et al[13] found a strong positive 
association between coenzyme Q10 (CoQ10) status and serum γGT activity in healthy participants. A gender-specific 
examination revealed differences between male and female volunteers regarding the association between CoQ10 status and 
serum γGT activity. In the second step, ubiquinol (Q10H2) supplementation (150 mg/d) caused a significant decrease in 
serum γGT activity (p < 0.001). γGT1 mRNA levels declined 1.49-fold after Q10H2 supplementation opposed to other liver 
enzymes (i.e., aspartate aminotransferase, AST) which were not affected by Q10H2 supplementation. This effect might be 
caused by gene expression. Serum γGT activity is associated with cardiovascular diseases. In a physiological range, activity 
of γGT is a potential early and sensitive marker of inflammation and oxidative stress. Overall, they provided preliminary 
evidence that higher Q10H2 levels improve oxidative stress via reduction of serum γGT activity in humans.  
The two last references show that the molecule of γGT may serve as an oxidative marker. This, not only cancels its 
study implication out as associated with an antioxidant drug, but also warrants it too. Successful drug is the one which 
involutes and improves the enzyme values until it coincides with the sham values or does not differ significantly from 
those. This is achieved in this experiment and there is the paradox: while the result is declared as non-significant, however, 
it is significant both statistically and clinically because a disturbed enzyme level was restored from significant to non-
significant level. 
Conclusions are that erythropoietin administration whether it interacted or not with reperfusion time has non 
significant short – term decreasing effects on γGT levels. It seems that either Epo itself exerts an over-restorating short-term 
influence on γGT levels, since these are found lower than sham operated ones, or γGT is enough valnerable in antioxidant 
capacity.  
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